Amgen’s Growth Story Relies Mainly On Continuing Plot Lines

Forecasts Mid-Single-Digit Revenue CAGR Through 2030

 
• By Mandy Jackson
Top view of vintage typewriter with books and copy space
Amgen is writing a growth story built on Repatha, Otezla, biosimilars and new launches • Source: Alamy

More from Business

More from Scrip